Last reviewed · How we verify
A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled Study to Evaluate the Efficacy and Safety of Jaktinib Hydrochloride Tablets in Participants Receiving the Best Available Treatment for Severe Novel Coronavirus Pneumonia (COVID-19)
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 168 eligible patients with severe novel coronavirus pneumonia.
Details
| Lead sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
|---|---|
| Phase | Phase 2 |
| Status | WITHDRAWN |
| Start date | 2022-09 |
| Completion | 2024-04-23 |
Conditions
- COVID-19
- Pneumonia
Interventions
- Jaktinib hydrochloride tablets
- Jaktinib hydrochloride tablets
- Placebo
Primary outcomes
- The proportion of Participants who develop death or respiratory failure. — 28 days after randomization
Respiratory failure is defined as Participants who on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation(ECMO) or on non-invasive ventilation or high-flow oxygen devices.